Nitric oxide is under clinical development by SaNOtize Research and Development and currently in Phase I for Oropharyngeal Candidiasis. According to GlobalData, Phase I drugs for Oropharyngeal Candidiasis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nitric oxide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nitric oxide overview

Nitric oxide (FabiSpray) is a free radical which acts as a bronchodilator agent. It is formulated as spray for inhalational route of administation. FabiSpray is indicated for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.

Nitric oxide is under development for the prevention and treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human papillomavirus verrucae plantaris(plantar warts), recurrent acute rhinosinusitis (RARS) and oropharyngeal candidiasis. The drug candidate is formulated as solution and administered as gargle, nasal spray or as a nasopharyngeal flush. It is being developed based on nitric oxide releasing solution (NORS) platform technology.

SaNOtize Research and Development overview

SaNOtize Research and Development (Sanotize) is a biotechnology company focusing on nitric oxide releasing solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Sanotize is headquartered in Vancouver, British Columbia, Canada.

For a complete picture of Nitric oxide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.